Website
Industry
Recent investment activity
KANDO id: 79860
Corporate information
Registration country
Company type
The corporate venture fund of the healthcare company RocheRelation
Funding rounds
Investment activity status
Active investor
Selected investments
Displaying 1 - 15 of 15| Company | Profile | Country | Date | Funding | ||
|---|---|---|---|---|---|---|
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM){kind=icon}
|
Alnylam Pharmaceuticals Inc | N/A | ||||
|
|
Ambit Biosciences Inc | A biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer. | Series D | |||
|
|
Conatus Pharmaceuticals Inc | Biotechnology company focused on the development of innovative human therapeutics to treat liver disease and cancer. | N/A | |||
|
|
CytomX Therapeutics | Developer of proteolytically-activated antibodies | Series B | |||
|
|
Halozyme Therapeutics Inc (Halozyme Inc) | Biopharmaceutical company developing & commercializing products targeting the extracellular matrix. | N/A | |||
|
|
Inimex Pharmaceuticals Inc | Series B | ||||
|
|
Intradigm Corp | N/A | ||||
|
|
IRX Therapeutics Inc | N/A | ||||
|
|
Nereus Pharmaceuticals Inc | Series E | ||||
|
|
Nereus Pharmaceuticals Inc | Series D | ||||
|
|
Addex Pharmaceuticals SA | Switzerland-based drug company focused on CNS disorders | N/A | |||
|
|
Aileron Therapeutics Inc | Developing a breakthrough proprietary peptide technology platform | N/A | |||
|
Horizon Discovery Ltd | Series C | ||||
|
|
Horizon Discovery Ltd | Series C | ||||
|
|
Opsona Therapeutics Ltd | Innate immune drug development company | Series C |